Trial · NCT01592370
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Experienced Drug Related Grade 3-4 AEs | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants That Experienced Drug Related Grade 3-4 SAEs | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Liver | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade - Thyroid | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All Treated Participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants That Experienced Drug-related Grade 3-4 AEs in the Nivolumab + Daratumumab Cohort | approximately up to 4 years | All treated participants in the nivo dara cohort | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants That Experienced Drug-related Grade 3-4 SAEs in the Nivolumab + Daratumumab Cohort | approximately up to 4 years | All treated participants in the nivo dara cohort | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade in the Nivolumab + Daratumumab Cohort - Hematology | approximately up to 4 years | All treated participants in the nivo dara cohort | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade in the Nivolumab + Daratumumab Cohort - Liver | approximately up to 4 years | All treated participants in the nivo dara cohort | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade in the Nivolumab + Daratumumab Cohort - Thyroid | approximately up to 4 years | All treated participants in the nivo dara cohort with at Least One On-Treatment TSH Measurement | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Best Overall Response | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All treated participants with available measurements (excluding Multiple Myeloma (MM) Group) | Percentage of participants | NUMBER |
| SECONDARY | Best Overall Response - Multiple Myeloma Group | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All Treated participants with available measurements in the Multiple Myeloma (MM) Group | Percentage | NUMBER |
| SECONDARY | Duration of Response | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to approximately 37 months Nivo Liri: approximately up to 4 years 1 month | All Responding participants (Complete Response and Partial Response) with available measurements (excluding Multiple Myeloma (MM) Group) | Months | MEDIAN |
| SECONDARY | Duration of Response - Multiple Myeloma Group | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month | All Responding participants (Complete Response and Partial Response) in the Multiple Myeloma (MM) Group | Months | MEDIAN |
| SECONDARY | Progression Free Survival | From date of randomization to date of progression or death, whichever occurs first (up to approximately 24 months) | All Treated Participants with available measurements | Months | MEDIAN |
| SECONDARY | Progression Free Survival Rate | From randomization to the specified timepoints (up to 48 months) | All Treated Participants with available measurements | Percentage of Participants | NUMBER |
| SECONDARY | Overall Survival | Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to3 years Nivo Liri: approximately up to 4 years 1 month | All Treated Participants with available measurements | Months | MEDIAN |
| SECONDARY | Number of Participants With PD-L1 Expression | At baseline (prior to start of study treatment) | All Treated Participants | Number of Participants | NUMBER |
| SECONDARY | Percentage Change From Baseline in the Modified Severity Weighted Assessment Tool (mSWAT) Score | From baseline (last measurement before start of study treatment) to last available measurement after start of study treatment (88 weeks for Nivo mono, 93 weeks for nivo+ipi, 25 weeks for nivo+liri) | All Treated Participants with cutaneous T Cell lymphoma and available measurements | Percent of change from baseline | MEAN |
| SECONDARY | Time to MRD Negativity Status in the Nivolumab + Daratumumab Cohort | approximately up to 4 years | All Randomized MRD Evaluable Subjects Achieving MRD Negativity | Months | MEAN |
| SECONDARY | Objective Response Rate in the Nivolumab + Daratumumab Cohort | approximately up to 4 years | All randomized participants in the nivo dara cohort | Percentage | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01592370/outcomes